Navigation Links
Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
Date:3/22/2013

CAMBRIDGE, Mass., March 22, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has received a Notice of Issuance from the U.S. Patent and Trademark Office (USPTO) for its patent application entitled "ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS", U.S. Patent No.: 8,410,088. The USPTO granted claims covering the novel small molecule EZH2 inhibitor EPZ-6438 (E7438), a drug candidate for a genetically defined type of non-Hodgkin lymphomas. The patent issuance marks Epizyme's first claims covering this chemical matter.

Epizyme is developing EPZ-6438 (E7438) in partnership with Eisai Co., Ltd. In March 2011, the two companies announced a worldwide partnership to discover, develop and commercialize therapeutics targeting EZH2, with Epizyme retaining an option to co-commercialize, co-develop and share profits for this program with Eisai in the United States.

About Epizyme, Inc.

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). To date, Epizyme has entered into therapeutic collaborations with Celgene, Eisai and GSK that have provided it with approximately $120 million in non-equity funding through December 31, 2012. 

For more information, visit http://www.epizyme.com.


'/>"/>
SOURCE Epizyme
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
2. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
3. CE Mark Granted for Wound Spray Based on Sangui Patent
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. ERT Granted Patents on Clinical Trial Participant Compliance
7. Revolutionary Tetrapod Quantum Dot Synthesis US Patent Granted
8. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
9. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
11. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2020)... ... January 24, 2020 , ... The plastic and reconstructive ... Center in New Jersey epitomize the notion that plastic surgery is much more than ... in popular media. , Over the last 20 years NJ Top Docs, Dr. Andrew ...
(Date:1/23/2020)... , ... January 22, 2020 , ... ... developments in the cosmetic surgery industry at two recent North American investor forums ... at the Canaccord Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 ...
(Date:1/22/2020)... (PRWEB) , ... January 21, 2020 , ... ... challenges with the precision of Genome editing. The partners have agreed to co-develop ... (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, the parties ...
(Date:1/10/2020)... and MALVERN, Pa. (PRWEB) , ... January 09, ... ... File (TMF) software and expert services, today announced the acquisition of Cunesoft, a ... functionality to meet the business objectives of life sciences companies. , Based in ...
Breaking Biology Technology:
(Date:1/22/2020)... Calif. (PRWEB) , ... January 21, 2020 , ... ... Robert Pozil to lead the company’s new Business Development Department. The move, which ... Mr. Pozil had been previously serving as the company’s Senior Vice President where ...
(Date:1/22/2020)... ... January 21, 2020 , ... ... integrating cold chain operations, developing transport validation strategies, supporting global regulatory applications, ... Inc. 5000 and the Houston Business Journal as a fastest growing company, ...
(Date:1/8/2020)... ... January 08, 2020 , ... R3 ... overnight shipping to its nationwide practice network partners. Not only does this ... volume in its Network the biologics themselves are less expensive. , Since the ...
Breaking Biology News(10 mins):